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Introduction
Parkinson´s disease (PD) is diagnosed based on the occurrence of bradykinesia, rigidity and tremor (Postuma et al., 2015) . However, PD symptomatology extends beyond the motor deficits and includes psychiatric symptoms, autonomic dysfunction, sleep disturbances, cognitive impairment and hyposmia (Poewe et al., 2017) . Disruption of motor function is principally caused by the progressive loss of the dopamine (DA) producing neurons of the substantia nigra pars compacta (SNc) (Bernheimer et al., 1973) . Symptomatic treatment in PD aims at restoring DA neurotransmission by stimulating DA D2 receptors (D2R), inhibiting monoamine oxidase B or catechol-o-methyltransferase, and/or administering 3, 4-dihydroxy-L-phenylalanine (L-DOPA) which is decarboxylated to DA (Poewe et al., 2017) . The major postsynaptic targets of SNc neurons are the striatal GABAergic medium spiny neurons (MSNs). The MSNs are divided in two distinct neurochemical and anatomical subpopulations: the prodynorphin (PDYN)/D1R+ neurons projecting directly to substantia nigra pars reticulata and the preproenkephalin (PENK)/D2R+ neurons projecting indirectly to substantia nigra pars reticulate via relays in the globus pallidus and the subthalamic nucleus (Gerfen and Surmeier, 2011) . Furthermore, these MSN subtypes have different involvement in motor programs as increased activity of PDYN/D1R+ neurons, but reduced activity of PENK/D2R+ neurons, stimulates locomotor activity (Bamford et al., 2018) . Elevated levels of DA in the dorsal striatum following L-DOPA administration enhance locomotor activity via both the striatal output pathways (Bamford et al., 2018) .
Unfortunately, repeated administration L-DOPA often leads to involuntary movements referred as LDOPA induced dyskinesias (LIDs) (Cenci et al., 1998; Poewe et al., 2017) .
A common method to cause DA depletion and induce experimental parkinsonism is to unilaterally inject 6-hydroxydopamine (6-OHDA) within the medial forebrain bundle (MFB) (Arbuthnott and Ungerstedt, 1970; Schober, 2004) . This model is often used to study anti-parkinsonian as well as dyskinetic actions of L-DOPA and other dopaminomimetic compounds (Cenci et al., 1998) .
The orphan GPCR, GPR88, is a potential therapeutic target against PD (Mizushima et al., 2000; Alavi et al., 2018) . Thus, in situ hybridization analysis of GPR88 mRNA has demonstrated predominant expression in the striatum and moderate levels of the transcript in the olfactory tubercle, the inferior olivary nucleus, amygdala and cerebral cortex (Mizushima et al., 2000; Massart et al., 2009) . Subcellular localization studies showed that GPR88 is highly expressed in both MSN populations in dendritic spines at proximity to corticostriatal synapses (Massart et al., 2009 ), Deletion of GPR88 in mice leads to hyperactivity and foraging deficiency due to the enhanced basal firing rate of MSNs associated with a facilitation of AMPA receptors signaling (Quintana et al., 2012; Rainwater et al., 2017) . Using the unilateral 6-OHDA model, it has previously been showed that 6-OHDA lesions led to opposite changes in GPR88 expression in the two MSN populations which were reversed by chronic administration of L-DOPA (Massart et al., 2009 ). Based on the abovementioned findings, we hypothesized that GPR88 may play an important role in PD and in modulating L-DOPA responses. We therefore used GPR88 wild type (WT) and knock-out (KO) mice to investigate the functional implications of GPR88 in several PD related conditions. First, we evaluated the influence of GPR88 on the anti-parkinsonian and dyskinetic side effect of LDOPA treatment. For this experiment, we used the unilateral 6-OHDA lesion model in both GPR88 WT and KO mice and studied rotational and dyskinetic behaviours upon repeated L-DOPA administration.
Second, we analysed the DA transporter (DAT) protein, monoamines and their metabolites as well as key neuroplastic genes of MSNs in unilaterally 6-OHDA lesioned GPR88 WT and KO mice which had undergone chronic L-DOPA treatment. Third, we examined the responses of GPR88 WT and KO mice towards tacrine-induced PD-like tremor. Fourth, we assessed spontaneous locomotion in GPR88 WT and KO mice. Fifth, since GPR88 KO mice exhibit spontaneous hyperlocomotion in a DAindependent manner and GPR88 is anatomically positioned to modulate the corticostriatal glutamate transmission, we performed fast analytical sensing technology (FAST) measures of glutamate in striata of GPR88 WT and KO mice.
Materials and methods

Animals
Adult male GPR88 WT and KO mice on a C57Bl6J background were provided by Charles River.
They were housed in temperature-and humidity-controlled rooms (20°C, 53% humidity) with a 12 h dark/light cycle. The mice had access to standard food pellets and water ad libitum. The experiments were approved by the local ethical committee at Karolinska Institute (15191-2017) and conducted in accordance with the European Communities Council Directive of 24 November 1986 (86/609/EEC).
Experiments performed in unilaterally 6-OHDA-lesioned GPR88 WT and KO mice
6-OHDA lesioning and treatment
15 WT and 16 KO male mice were anesthetized with 80 mg/kg ketamine (i.p.; Parke-Davis) and 5 mg/kg xylazine (i.p.; Bayer), pretreated with 25 mg/kg desipramine (i.p.; Sigma-Aldrich) and 5 mg/kg pargyline (i.p.; Sigma-Aldrich), placed in a stereotaxic frame, and injected, over 2 min, with 3 µg of 6-OHDA in 0.01% ascorbate (Sigma-Aldrich) into the median forebrain bundle (MFB) of the right hemisphere. The coordinates for injection were AP, −1.1 mm; ML, −1.1 mm; and DV, −4.75 mm relative to bregma and the dural surface (Paxinos and Franklin, 2011) . Two weeks after unilateral 6-OHDA administration, we validated the lesion by treating the mice with 1 mg/kg apomorphine (i.p;
Sigma-Aldrich) and assessed rotational behavior. All mice rotated contralaterally and none of them was excluded from the study. Four weeks after surgery, mice were treated with saline or 10/7.5 mg/kg LDOPA/benserazide (i.p.; Sigma-Aldrich) once daily for 21 days. Animals were killed 1 h after the last injection. For brevity, L-DOPA/benserazide treatments are solely labeled L-DOPA throughout this article.
Measurements of rotations and abnormal involuntary movements (AIMs)
For measurements of rotations and AIMs, unilaterally 6-OHDA-lesioned mice were treated with LDOPA and placed in individual cages. The number of ipsilateral and contralateral rotations was thereafter counted for 30 min on days 1, 7, 14 and 21 to measure motor responses to L-DOPA, which are known to supersensitize upon chronic L-DOPA administration (Bibbiani et al. 2001) . Immediately after the quantification of rotational behaviors, the incidence of AIMs was scored for 5 min (Zhang et al. 2008 ). This procedure was adapted from a validated rodent scale (Lundblad et al. 2004 ). The AIMs were classified into four subtypes: Forelimb, Orofacial, Axial, and Locomotive behaviors. Enhanced manifestations of normal behaviors such as grooming, gnawing, rearing, and sniffing were not included in the rating. The severity of each AIM subtype was assessed using scores from 0 to 4 (0: absent, 1: occasional, i.e., present less than 50% of the time; 2: frequent, i.e., present more than 50% of the time; 3: continuous, but interrupted by strong sensory stimuli and 4: continuous, not interrupted by strong sensory stimuli).
Autoradiographic detection of the DA transporter (DAT)
This method was used as an additional validation of the lesioning described in section 2.2.1.. Slides mounted fresh frozen sections (12 µm thick) at the level of striatum were preincubated in 50 mM Tris-HCl/120 mM NaCl (pH 7.5) for 20 min. Incubation in binding buffer (50 mM Tris-HCl/120 mM NaCl, pH 7.5/1 µM fluoxetine) was conducted with 50 pM of the DAT ligand (125I) RTI55 (Perkin-Elmer Life Sciences, Boston, USA) for 60 min. To detect nonspecific binding, 100 µM nomifensine was added to the assay. The slides were washed 2 × 10 s in ice-cold binding buffer, rapidly dipped in deionized water, dried, and exposed to autoradiographic films (BioMax MR, Merck Eurolab, Sweden) in X-ray cassettes at −20°C for 7 days before being developed (Kodak D19, Unifix).
In situ hybridization (ISH) experiments
In situ hybridization was performed in cryostat (Leica CM 3050 S) fresh frozen sections (12 µm thick) as previously described (Svenningsson et al., 1997) . Briefly, 35S-labelled anti-sense and sense cRNA probes were prepared by in vitro transcription from cDNA clones corresponding to fragments of activity-regulated cytoskeleton-associated protein (ARC), proenkephalin (PENK), prodynorphin (PDYN) and glutamate decarboxylase 67 (GAD67). The transcription was performed from 50-100 ng of linearized plasmid using (35S) UTP (1000 Ci/mmol) and SP6, T3, T7 RNA polymerase. Cryostat sections were post fixed in 4% PFA for 5 min at room temperature, rinsed twice in 4×sodium chloride-sodium citrate buffer (SSC) and placed into 0.25% acetic anhydride in 0.1 M triethanolamine/4×SSC (pH 8) for 10 min at room temperature. After dehydration in graded alcohols, the sections were hybridized overnight at 55°C with 35S-labelled probe in 50 µl of hybridization solution (20 mM Tris-HCl/1 mM EDTA/300 mM NaCl/50% formamide/10% dextran sulphate/1×Denhardt's/250 µg/ml yeast tRNA/100 µg/ml salmon sperm DNA/0.1% SDS/0.1% sodium thiosulphate). The slides were washed in 4×SSC (5 min, four times), RNAse A (20 µg/ml) (20 min, at 37°C), 2×SSC (5 min, twice), 1×SSC(5 min), 0.5×SSC (5 min) at room temperature, and rinsed in 0.1×SSC at 65°C (30 min, twice) (all washes contained 1 mM DTT), before being dehydrated in graded alcohols. The slides were then exposed on X-ray films for four to 28 days.
Fluorescent ISH (RNAscope) were performed using the RNAscope Multiplex Fluorescent Assay (Advanced Cell Diagnostics). Cryostat (Leica CM 3050 S) fresh frozen sections (12 µm thick) were post fixed in 4% PFA for 15 min at 4°C and dehydrated in graded alcohols. Afterwards, it was applied Protease IV (Advanced Cell Diagnostics) for 30 min at room temperature. Then, the sections were hybridized with the probes: Pdyn (Mm-Pdyn-C3, cat. 318771-C3) and Arc (Mm-ArcC2, cat. 316911-C2) for 2 h at 40 °C. The hybridization step was followed by standardized steps of amplification (Amp 1-FL 30 min at 40 °C, Amp 2-FL 15 min at 40 °C, Amp 3-FL 30 min at 40 °C, Amp 4C-FL 15 min at 40 °C). After the last amplification step the sections where counterstained with DAPI (Advanced Cell Diagnostics) and mounted with Dako fluorescent mounting medium. Sections were imaged on a Carl Zeiss LSM 880 confocal microscope using a 63× 1.4 NA oil immersion objective. Z-stacks of 5-7 µm thickness were obtained in each caption.
Analysis of neurotransmitters in mouse brain by HPLC
Methods for sample preparation and high-performance liquid chromatography (HPLC) with electrochemical detection (ECD) were based on two previously published protocols (Hubbard et al., 2010; Yang and Beal, 2011) and are described in detail below.
Chemicals and reagents: L-Noradrenaline hydrochloride (NA), 3,4-Dihydroxyphenylacetic acid (DOPAC), dopamine hydrochloride (DA), 5-hydroxyindole-3-acetic acid (5-HIAA), homovanillic acid (HVA), serotonin hydrochloride (5-HT), 3-methoxytyramine (3-MT), vanillylmandelic acid (VMA), epinephrine (EPI), dihydroxyphenylalanine (DOPA), 3-methoxy-4-hydroxyphenylglycol (MHPG), acetonitrile (Chromasolv Plus), monobasic sodium phosphate, ethylene-diamine-tetra-acetic acid (EDTA) disodium salt, 1-octanesulfonic acid (OSA) sodium salt, triethylamine (TEA), 85% phosphoric acid, 70% perchloric acid (PCA), and sodium bisulfite were purchased from SigmaAldrich. HPLC-grade water was produced using a Milli-Q Ultra-Pure water system (Merck Millipore).
Preparation of tissue samples: Ice-cold 0.1 M PCA was added to pre-weighed tissue samples at approximately 10-20 µl PCA per mg of tissue. Samples were then immediately homogenized using an ultrasonic processor (EpiShear Probe Sonicator; Active Motif) with a 3 mm probe at 20% amplitude for 6 seconds. Samples were incubated on ice for 10 minutes, vortexed and centrifuged at 16000 x g for 15 minutes at 4°C. Resulting supernatants were transferred to centrifugal filter tubes with 0.2 µm nylon membrane inserts and centrifuged at 5000 x g for 3 minutes. Eluents were immediately stored at -80°C and subjected to HPLC-ECD analysis within 6 days. Standard solutions of 3-MT, 5-HT, 5-HIAA, DA, DOPAC, DOPA, HVA, VMA, EPI, NA and MHPG were prepared at 500 µg/ml in 0.1 M PCA on the day before the assay. From these solutions, a mix containing all standards was prepared in 0.1 M PCA with a concentration of 10 µg/ml per standard, and this mix was stored as aliquots at -80°C. On the next day, this mix was further diluted with 0.1 M PCA to obtain final standard concentrations of 200, 100, 50, 10, 5, 2 and 1 ng/ml. Calibration curves were obtained with the Chromeleon software through linear regression of peak area versus concentration. Coefficients of determination were 0.999.
Standard solutions and calibration:
Instrumentation and analysis: The HPLC-ECD system was a Dionex Ultimate 3000 series (all parts from Dionex, ThermoFisher Scientific) comprising an ISO-3100BM HPLC pump, WPS-3000TBSL analytical autosampler with temperature control, SRD-3200 solvent rack with built-in 2-channel vacuum degasser, Coulochem III detector with thermal organizer module, and a 5011A coulometric analytical cell. Analyte separation was performed on a Dionex C18 reversed-phase MD-150 3.2 mm x 150 mm column (3 µm particle size). Column and analytical cell were kept at 45°C. The mobile phase, which was pumped at a flow rate of 0.5 ml/min, consisted of 75 mM monobasic sodium phosphate, 3.1 mM OSA, 100 µl/l TEA, 25 µM EDTA and 10% acetonitrile (v/v), and was filtered through a nylon membrane (pore size 0.2 µm). The pH was adjusted to 3.0 with 85% phosphoric acid before degassing of the mobile phase for approximately 5 minutes and equilibration overnight on the HPLCECD system. For detection of neurotransmitters and metabolites, the first and second analytical cells were set to -100 mV and +300 mV, respectively. Processed tissue samples were thawed on ice in the dark for about 1 h before analysis, placed in the autosampler and kept at 5°C before injection.
Injection volume was 20 µl per sample. Chromatograms were acquired with Dionex Chromeleon 7 software over an acquisition time of 15 minutes. Analyte concentrations in tissue samples were expressed as ng/mg
Experiments performed in normal GPR88 WT and KO mice 2.3.1. Tacrine-induced tremulous jaw movements
To assess 3-7 Hz tremulous jaw movement, normal mice were treated with tacrine (2.5 mg/kg i.p.;
Sigma). After 20 min, they were placed in a clean cage situated in an elevated position to allow complete observation of the experimental animal. After 10 min of habituation, tremulous jaw movements-defined as vertical and purposeless deflections of the lower jaw (Salamone et al., 2001 )were manually scored for 5 min. Yawns, tongue protrusions, and stereotypes, such as grooming, were not included in the evaluation.
Open-field test to measure locomotion activity
The test was performed for 30 min in a 46 × 46 cm2 arena with gray floor and walls. The arena was illuminated by reflected light, providing an intensity of 30 lux on the floor of the arena. The arena was cleaned with 70% ethanol after each test session to eliminate olfactory cues. Video tracking was performed using a video camera mounted in the ceiling and analyzed by EthoVision XT11.5 (Noduls) software.
FAST measurements of glutamate release.
GPR88 WT or KO mice were anesthetized with isoflurane (3% for induction, 0.7-1% for maintenance) and mounted in a stereotaxic frame (David Kopf Instruments) fitted with a Cunningham mouse adapter (Stoelting Co.). Small cranial windows were drilled over the striatam (AP: +1.3; ML: ±1.5; DV: −2.5 versus bregma), and microelectrode arrays (MEAs) were inserted into dorsal striatum of the intact and DA-depleted hemispheres. As previously described (Alvarsson et al., 2015; Stan et al., 2014; Hascup et al., 2008) , glutamate dynamics were assessed on a subsecond timescale by MEA recordings with two of four electrode sites coated with L-glutamate oxidase enzyme, which breaks down L-glutamate into α-ketoglutarate and peroxide (H2O2). By using constant voltage amperometry with application of a fixed potential, the H2O2 was oxidized, with electron loss, and the resulting current was recorded using a Fast Analytical Sensing Technology-16 (FAST-16 MKII) electrochemistry instrument (Quanteon). Depolarization-induced glutamate release was induced by an isotonic solution of 70 mM KCl ejected for 1 second at 1 minute intervals through a glass micropipette positioned at a distance of 50-100 µm from the MEA recording sites. For exogenously applied glutamate, 30 µM of glutamate was applied in the same way. A MATLAB graphic interface was used to calculate concentrations of glutamate from an average of 3-5 amplitudes per mouse. The area under curve (AUC) of the glutamate waveform, maximum amplitude of evoked glutamate (Evoked Glu, exclude amplitude less than 0.5 µM) and the decay time from maximum amplitude to 80% decay (T80) were measured. The tonic glutamate levels were determined as the current recorded on the sentinel sites subtracted from the current on the glutamate recording sites (Burmeister et al. 2002; Hascup et al. 2010 ).
Data Analysis and Statistics
Autoradiograms from ligand binding autoradiography and ISH experiments were digitized using a Dia-Scanner (Epson Perfection 4870 PHOTO). Optical density values were measured using Image J (1.52h, Wayne Rasband National Institutes of Health, USA). Statistical significance of the results was assessed by using Student's t-test for paired observations (comparisons with baseline within single groups) or three way ANOVA multiple comparison test followed by Fisher's LSD post hoc test.
Pvalues, degrees of freedom and F values are detailed in the results part. For Student's t-test we used Graph Pad Prism 7.0. For three way ANOVA we used Stata 12.0. The individual group outliers were identified through quartile ± 1.5 interquartile range and removed.
Results
Unilaterally 6-OHDA-lesioned GPR88 KO mice make increased L-DOPA induced contralateral rotations but reduced abnormal involuntary movements
Our 6-OHDA MFB lesioning protocol causes near-complete reductions of DAT in both GPR88 WT and KO mice ( Figure 1A) . The administration of L-DOPA to unilaterally 6-OHDA lesioned animals leads to contralateral rotations and abnormal involuntary movements (AIMs), behaviors which sensitize upon repeated L-DOPA treatment. Prior to using this paradigm, unilaterally 6-OHDA lesioned GPR88 KO and WT mice were assessed by the number of apomorphine induced rotations and showed no genotype difference (Student's unpaired t test, p = 0.5713; Figure 1B ). The therapeutic effect of L-DOPA is interpreted by measuring contralateral rotations while dyskinesia is assessed by the frequency of abnormal involuntary movements (AIMs) (Cenci et al., 1998) . GPR88 WT and KO mice were thereafter treated repeatedly with L-DOPA and a two way ANOVA showed a significant difference in the contralateral rotational turns between the groups (Table S1 ). Post hoc analysis showed that administration of L-DOPA for 3 weeks led to a significant increased number of contralateral rotations within 30 minutes in both WT and KO animals (Fisher's LSD post hoc test: WT day 14 vs WT day 1, p = 0.01; WT day 21 vs WT day 1, p < 0.0001; KO day 14 vs KO day 1, p = 0.0006; KO day 21 vs KO day 1, p < 0.0001; Figure 2A ). The same post hoc test also revealed that during all the time points, GPR88 KO mice had significantly higher rotational rate than the WT mice (Fisher's LSD post hoc test: WT day 1 vs KO day 1, p = 0.048; WT day 7 vs KO day 7, p = 0.0435;
WT day 14 vs KO day 14, p = 0.0022; WT day 21 vs KO day 21, p = 0.0006; Figure 2A ). Along with the enhanced L-DOPA induced rotational response, GPR88 KO mice showed considerably lower AIMs scores. A two way ANOVA revealed significant difference in the total number of AIMs (Table   S1 ). A post hoc test showed that GPR88 KO mice exhibited significantly less AIMs than WT mice, on the 14th and 21st day of treatment (Fisher's LSD post hoc test: WT day 14 vs KO day 14, p = 0.0001;
WT day 21 vs KO day 21, p < 0.0001; Figure 2B ). Furthermore, WT mice displayed significantly higher number of AIMs on 14th and 21st day compared with the 7th day (Fisher's LSD post hoc test:
WT day 14 vs WT day 7, p = 0.0003; WT day 21 vs WT day 7, p < 0.0001; Figure 2B ). Conversely, GPR88 KO showed only significantly more AIMs on the 21st day when compared to the 7th day (Fisher's LSD post hoc test: KO day 21 vs KO day 7, p = 0.0293; Figure 2B ). Detailed subscore analyses of AIMs ( Figures 3A-D) with two way ANOVAs showed that axial and orofacial AIMs were significantly different among the genotypes and the time points (Table S2 ). The same test also showed that forelimb AIMs were significantly different only among the genotypes, while locomotive AIMs did not show any significant differences (Table S2 ).
Unilaterally 6-OHDA-lesioned GPR88 KO mice differentially regulates the mRNA of L-DOPA induced genes
As aforementioned, we observed that GPR88 KO mice simultaneously have augmented rotational behavior and diminished AIM scores in comparison with the WT mice. These distinct behavioral responses were not due to a differential neurotoxic response towards 6-OHDA as autoradiographic detection of DAT showed no genotype difference ( Figure 1A) . To obtain insight in the molecular mechanisms underlying the beneficial L-DOPA responses in GPR88 KO mice, we decided to study selected mRNA changes in striatal sections from the same animals which had undergone the behavioral assessments upon chronic L-DOPA treatment. It has been determined that both acute and chronic L-DOPA treatments induce the mRNA expression of immediate early genes (IEGs), like cFOS, ARC and EGR-1 (Fisone and Bezard, 2011) . Moreover, it is well-established that chronic LDOPA administration increases the transcription of PENK, PDYN and GAD67 mRNAs (Cenci et al., 1998; Picconi et al., 2018; Sgroi and Tonini, 2018) . Furthermore, there are studies which state that contralateral rotations and AIMs are independently correlated with PDYN and PENK elevation respectively (Breger et al., 2013; Sgroi and Tonini, 2018) . Based on these previous studies, we decided to perform experiments with 35 S labeled antisense probes towards ARC, PENK, PDYN and GAD67 mRNAs. Three way ANOVA showed significant difference of PDYN, GAD67 and ARC transcripts between the groups (Table S3 ). Post hoc analysis revealed that L-DOPA treated GPR88 KO mice had a smaller increase of PDYN and GAD67 mRNA than the WT (Fisher's LSD post hoc test: WT lesion LDOPA vs KO lesion L-DOPA, PDYN: p < 0.0001; Figure 4A ; GAD67: p = 0.015; Fig 4C; ARC: p < 0.0001; Fig 4D) . Furthermore, post hoc analysis unveiled that GAD67 transcripts were significantly higher in the lesioned side of the L-DOPA treated WT animals while this effect was absent in the LDOPA treated KO mice (Fisher's LSD post hoc test: WT intact L-DOPA vs WT lesion L-DOPA, p = 0.007; KO intact L-DOPA vs KO lesion L-DOPA, p = 0.185; Figure 4C ). In contrast to the aforementioned genes, ARC mRNA was more increased in GPR88 KO than WT mice (Fisher's LSD post hoc test: WT lesion L-DOPA vs KO lesion L-DOPA, p < 0.0001; Figure 4D ). Moreover, three way ANOVA showed that PENK transcripts were significantly affected by the hemisphere factor (Table S3 ). Post hoc analysis revealed that PENK did not show any significant difference between GPR88 WT and KO mice (Fisher's LSD post hoc test: WT lesion L-DOPA vs KO lesion L-DOPA, p = 0.349; Figure 4B ). We used fluorescent ISH (RNAscope) with PDYN and ARC probes in 3 WT and 3 KO mice, to identify the ARC and PDYN positive cells in the L-DOPA treated lesioned striata ( Figure   4E ). Approximately 90% of ARC positive cells express PDYN in both WT and KO mice (Cell type: F(1,8) = 1844, p < 0.0001; Genotype: F(1,8) = 2.482, p = 0.1538; Cell type × Genotype: F(1,8) = 0.073, p = 0.79) ( Figure 4F) . Consequentlty, the neurons that show less PDYN in GPR88 KO mice than in WT animals are the same as those that have more transcripts of ARC. Taken together, our ISH data indicate that GPR88 KO mice display a lower upregulation of PDYN and GAD67 but a higher upregulation of ARC after L-DOPA administration.
GPR88 KO mice display altered levels of striatal 3-methyltyramine (3-MT) and 5hydroxytryptamine (5-HT)
To further investigate the mechanisms behind these behavioral aspects after the administration of LDOPA, we furthermore performed HPLC with focus on striatal monoamines and their metabolites.
Three way ANOVA showed a significance between WT and KO only for 3-MT and 5-HT (Tables S4,   S5 , S6). Post hoc test revealed that GPR88 KO mice had lower 3-MT levels in the intact hemisphere (Fisher's LSD post hoc test: WT intact saline vs KO intact saline, p = 0.014). Moreover, L-DOPA increased the amount of 3-MT in the intact side of GPR88 KO mice (Fisher's LSD post hoc test: WT intact saline vs WT intact L-DOPA, p = 0.131; KO intact saline vs KO intact lesion, p = 0.026; Figure   5A ). This effect was not observed in WT mice (Fisher's LSD post hoc test: WT intact saline vs WT intact L-DOPA, p = 0.131; Figure 5A ). Post hoc test also revealed that GPR88 KO mice had lower 5HT than the WT, in the lesioned hemisphere (Fisher's LSD post hoc test: WT lesion saline vs KO lesion saline, p = 0.002; Figure 5B ). Moreover, the same test showed that 5-HT decreased after the administration of L-DOPA in the lesioned hemisphere of WT mice, while there was no effect in GPR88 deficient mice (Fisher's LSD post hoc test: WT lesion saline vs WT lesion L-DOPA, p = 0.014; KO lesion saline vs KO lesion L-DOPA, p = 0.085; Figure 5B ).
Normal GPR88 KO mice show increased locomotion and reduced tacrine-induced tremulous jaw movements
The total distance that GPR88 KO and WT mice moved in an open field was measured for 30 minutes.
In accordance with previous studies (Maroteaux et al., 2018; Meirsman et al., 2017; Meirsman et al., 2016b; Quintana et al., 2012) , GPR88 KO animals performed significantly longer paths within the field in comparison with the WT (Student's unpaired t test: t (2.3), p = 0.03; Figure 6A -C).
We studied the influence of GPR88 in PD-like induced tremor. The administration of tacrine, an acetylcholinesterase inhibitor, causes tremulous jaw movements (TJM) in a frequency which resembles that one of PD tremor (3-7 Hz) (Salamone et al., 2001) . GPR88 KO animals had lower number of TJMs than the WT counterparts (Student's unpaired t test: t (8.8), p < 0.0001, Figure 6D ).
Tonic and evoked glutamate release is elevated in striatum of normal GPR88 KO mice
Corticostriatal glutamate is known to have a central position in the motor sensitization towards dopaminomimetic compounds (Picconi et al., 2018; Duty, 2012; Johnson et al., 2009; Gerfen and Surmeier, 2011) . By using in vivo FAST glutamate recording, we measured the amplitude of evoked and tonic release in dorsal striata from GPR88 WT and KO mice ( Figure 7A) . Interestingly, we observed substantially increased glutamate striatal release in the GPR88 KO animals. There are higher concentration of both evoked and tonic glutamate release (Student's unpaired t test, Evoked: t (3.8), p = 0.0010; Figure 7B ; Tonic: t (2.5), p = 0.0234; Figure 7C ). Moreover the AUC of the glutamate levels in GPR88 KO mice was larger than the one of the WT mice (Student's unpaired t test, t (5.9), p < 0.0001; Figure 7D ). An increased AUC relies on higher peaks and on slower return to baseline. The slower decay of the glutamate signal is dependent on the clearance from the extracellular space. To quantify glutamate clearance we used the T80 time and found that it was significantly increased in the GPR88 KO striata compared to WT (Student's unpaired t test, T80: t (2.8), p = 0.0101; Figure 7E ). It is known that astrocytes are largely responsible for removing synaptic glutamate, but GPR88 has not been detected in any glial cell (Massart et al., 2009) . We therefore hypothesized that the T80 rise depends upon the high wave peak amplitude. In order to test this hypothesis, we performed FAST recording in striata of GPR88 WT and KO animals by injecting glutamate solution without KCl ( Figure 7F ). The exogenous application of glutamate gave rise to a glutamate wave that was similar in both GPR88 WT and KO (same peak amplitude and T80) (Student's unpaired t test, Peak amplitude: t (0.14), p = 0.8873; Figure 7G ; t (0.01), AUC: p = 0.9918; Figure 7H ; t (0.5), T80: p = 0.6115; Figure   7I ). With this experiment, we confirmed that the increased T80 is an outcome from the high peak amplitude. Our findings indicate that GPR88 regulates the corticostriatal glutamate release.
Discussion
There are several possible explanations for the core observations that GPR88 KO mice display an enhanced rotational response to L-DOPA (related to potential therapeutic activity) whereas the induction of AIMS (a readout of potential induction of dyskinesia) is reduced. First, while both D1 and D2 agonism increase contralateral rotations, D2 agonists are less prone to develop AIMs (Carta et al., 2008; Schintu et al., 2016; Sgroi et al., 2016) . Heightened L-DOPA-induced rotational response corresponds to therapeutical efficacy as it represents the locomotive induction by L-DOPA in the DAdepleted striatum (Lundblad et al., 2005) . However, locomotive AIMs can be misleading due to their direct link with the rotational response (Lundblad et al., 2005) . For this reason, there are studies that exclude locomotive AIMs when calculating the total AIM score (Lundblad et al., 2005) . Previous studies have shown that GPR88 KO show higher sensitivity in MSNs' D2 receptors Logue et al., 2009 ). This may then explain partially the heightened contralateral rotational rate without enhancement of AIMs, observed in GPR88 KO. Second, increased striatal expression of RGS4 mRNA after L-DOPA is positively correlated with the AIM score (Ko et al., 2014) .
Downregulation of RGS4 in GPR88 KO has previously been reported and may also account to their protective effect against AIMs (Quintana et al., 2012) . Third, there is evidence that M4, which is a Gi muscarinic receptor, is inhibiting LIDs (Shen et al., 2015) . Due to the Gi coupling of GPR88, KO mice may have higher baseline levels of cAMP that hamper the signaling of M4 upon activation (Jin et al., 2014) .
In addition, at the cellular level, the present data are also in accordance with work showing that the occurrence of AIMs correlates with the levels of levels of PDYN and GAD67 in experimental parkinsonism (Cenci et al., 1998) . Furthermore, our data reflected that the increased contralateral rotational rate of GPR88 KO are associated with the ARC mRNA levels. Interestingly, these transcriptional changes of PDYN and ARC in GPR88 KO striata are observed simultaneously on the same D1 MSNs. Both ARC and PDYN are upregulated by L-DOPA through cAMP/PKA/ERK pathway activation (Fisone and Bezard, 2011) . Nevertheless, there are studies which show that the levels of cyclic nucleotides cAMP and cGMP are fluctuating in both hemispheres after the chronic treatment of L-DOPA (Giorgi et al., 2008; Sancesario et al., 2014) . Specifically, there is a transient decrease of cAMP and cGMP during the peak of LIDs and a subsequent increase in the dyskinesiafree state (Sancesario et al., 2014) . As GPR88 is a Gi coupled receptor, its absence may counteract such decrease of cAMP and cGMP levels in the dyskinetic phase. There is possibility that ARC and PDYN genes are differentially affected by the L-DOPA induced fluctuations of the cyclic nucleotides.
Consequently, lack of GPR88 increases ARC and decreases PDYN, probably due to smaller reductions of cAMP/cGMP levels during L-DOPA treatment. These transcriptional alterations may lead to enhanced rotational rate and fewer number of AIMs respectively.
In agreement with a role of GPR88 in 5-HT transmission, the present HPLC data indicate an additional mechanism whereby GPR88 may affect AIMs. GPR88 ISH data from the Allen brain atlas ISH database (image code: 79567811_149) denote the presence of GPR88 transcripts in dorsal raphe which is the major source of forebrain projecting 5-HT neurons. The pathophysiology of LID includes the displacement of 5-HT and release of "false" DA by serotoninergic terminals (Carta et al., 2007; Svenningsson et al., 2015; De Deurwaerdère et al., 2017) . We could, indeed, find such a displacement of striatal 5-HT in the L-DOPA-treated WT mice. However, in GPR88 KO mice striatal 5-HT levels were unaffected by L-DOPA. Furthermore, we found significant reduced levels of 3-MT in intact striata of GPR88 KO mice which was normalized after L-DOPA administration. 3-MT is a catecholamine metabolite that occurs after the O-methylation of DA by catechol-O-methyl transferase (COMT) (Karoum et al., 1994) . This reaction is considered to occur mostly in the extracellular space outside of DA neurons and reflects DA release rate (Karoum et al., 1994) . It has been previously reported that GPR88 KO mice display lower striatal DA levels, which is in accordance with our results (Meirsman et al., 2016a) . The alterations in DA metabolism in GPR88 KO mice may be adaptations to the aberrant intrinsic activity of MSNs and consequences on basal ganglia circuitry. The mechanism underlying this discrepancy remains to be studied, but it could underlie the reduced number of AIMs following L-DOPA in GPR88 KO mice.
Along with the potentiation of anti-parkinsonian action of L-DOPA in GPR88 KO mice, we found that these mice exhibits reduced PD-like tremor in response to tacrine. Tacrine is a potent acetylcholinesterase inhibitor which leads to an excess of striatal acetylcholine produced by the cholinergic interneurons (CINs) (Lehmann and Langer, 1983) . The striatal expression of GPR88 is restricted to MSNs and is not found in CINs (Quintana et al., 2012; Massart et al., 2009 ), so we conclude that the tremor reducing actions in GPR88 KO mice are indirect. A possible D1-MSN hyperactivity and increased intracellular cAMP in GPR88 KO mice could counteract the inhibitory action of M4 cholinergic receptors which regulate tremor (Salamone et al., 2001; Oldenburg and Ding, 2011; Shen et al., 2015; Jin et al., 2014) .
In line with previous work, it was observed that GPR88 KO mice had enhanced locomotor activity in an open field. GPR88 is confined on both types of MSNs, but previous studies have shown that deleting the receptor in D2-MSNs is adequate to produce a hyperactive phenotype (Meirsmann et al., 2017) . It has been observed that extracellular levels of DA are decreased in GPR88 KO mice (Meirsman et al., 2016a) . Our HPLC results showed a significant decrease in striatal 3-MT of GPR88 KO, though DA and other DA metabolites where unchanged. Thus, the hyperactivity in the GPR88 KO mice is not associated with enhanced striatal levels of DA and its metabolites.
Since GPR88 KO mice appear to exhibit a DA-independent hyperlocomotion, we studied glutamate levels in these mice. Our data from striatal FAST recordings suggest that GPR88 is a negative regulator of glutamate release in striatum. This effect could be interpreted as the outcome of deletion of GPR88 either on corticostriatal neurons or MSNs. Electron microscopy studies have revealed that GPR88 is located in postsynaptic submembranous areas around the dendrites and within the nuclei (Massart et al., 2009; Massart et al., 2016) . In the same studies no axonal GPR88 immunoreactivity was detected (Massart et al., 2009) . ISH images from Allen Brain Atlas ISH database (image code: 79567811_357) show that GPR88 demonstrates notable expression levels in corticostriatal projection layers II/III and V. This cortical expression pattern on pyramidal neurons agrees with the data of previous studies (Sohur et al., 2014; Massart et al., 2016; Arefin et al. 2017; Ehrlich et al., 2018) . As a consequence, the increased glutamate release that we observe could be explained through the lack of an inhibitory influence of GPR88 on corticostriatal neurons. However, the predominance of GPR88 expression in striatum sets the possibility that the higher glutamate release also involves MSN derived mechanisms. Deletion of GPR88 affects the phosphorylation of GluR1 subunit, facilitating AMPA receptor activation, and the phosphorylation of DARPP-32 which are known to be crucial players for the long term potentiation (LTP) and depression (LTD) in MSNs (Quintana et al., 2012; Bateup et al., 2010; Calabresi et al., 2000; Huang, 1997) . This process could involve several retrograde signaling molecules like nitric oxide, adenosine and endocannabinoids which regulate glutamate release (Huang, 1997; Bamford et al., 2018) . With regards to endocannabinoid retrograde signaling, a critical molecule for their postsynaptic production is RGS4 (Lerner and Kreitzer, 2012) . The reported lower striatal levels of RGS4 in GPR88 KO mice could lead to lower endocannabinoids and less retrograde inhibition of glutamate release (Lerner and Kreitzer, 2012; Quintana et al., 2012) .
There is intense activity in developing ligands at GPR88. Recent studies have used a bloodbrainbarrier permeable synthetic GPR88 agonist, RTI-13951-33, and showed beneficial actions against ethanol addiction in mice (Jin et al., 2018; Jin et al., 2016) . Based on the current work it will be important to develop brain penetrant GPR88 antagonists to determine whether pharmacological blockade of GPR88 will promote anti-parkinsonian actions of L-DOPA while reducing its side effects.
Conclusion
Taken together, GPR88 KO mice exhibit increased basal locomotion, increased motor responsivity towards L-DOPA in the unilateral 6-OHDA lesion model and reduced tacrine-induced tremors.
Meanwhile, GPR88 KO mice develop less AIMs in response to repeated L-DOPA. The graphical summary of our data is shown in Graphical Abstract. These data indicate that antagonism of GPR88 alone and/or in combination with L-DOPA may be useful for the symptomatic treatment of PD. GPR88 KO mice have lower 3-MT than the WT in the intact side which is going back to WT levels after the administration of L-DOPA. 5-HT is negatively affected by the 6OHDA in GPR88 KO mice but not in the WT. L-DOPA reduces striatal 5-HT amount in the lesioned striata of WT mice but not in 
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